A new deep learning challenge has been launched by the UEF Cancer AI research te...
BINGHAMTON, N.Y. — The rapidly evolving nature of digital media presents a chall...
For release: Dec. 5, 2023 Contact: Cory Nealon, cmnealon@buffalo.edu University ...
The energy consumption of data centers and information and communication technol...
BELLINGHAM, Washington, USA — On 1 April 2024, Takashige Omatsu, a professor at ...
SYDNEY, Dec. 6, 2023 – Australia’s most iconic sound is almost certainly the did...
Eating or being eaten, competing for resources – these are certainly the best-kn...
In southern Germany just north of the Danube, there lies a large circular depres...
SYDNEY, Dec. 6, 2023 – Table tennis has been played for decades as a more access...
SYDNEY, Dec. 6, 2023 – A bundengan wears many hats – and is one too. This portab...
Roche has made a resounding entry into the obesity market with a whopping upfron...
Aficamten is under clinical development by Cytokinetics and currently in Phase I...
TTI-101 is under clinical development by Tvardi Therapeutics and currently in Ph...
Ketamine ER is under clinical development by Douglas Pharmaceuticals and current...
SIM-325 is under clinical development by TCR Cure Biopharma Technology and curre...
Latozinemab is under clinical development by Alector and currently in Phase III ...
